Bayer Bolsters Nucleic Acid Diagnostics Portfolio With VGI Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Bayer Diagnostics will gain the only FDA-approved HIV sequencing resistance test available in the U.S. through its roughly $60 mil. cash acquisition of Visible Genetics, Inc
You may also be interested in...
Bayer’s Purchase Of Schering AG Creates $4.5 Bil. Diagnostics Company
Bayer's purchase of Schering AG will add imaging agents to the firm's diagnostics portfolio and boost testing-related revenue by roughly two-thirds to $4.5 bil. annually
Bayer’s Purchase Of Schering AG Creates $4.5 Bil. Diagnostics Company
Bayer's purchase of Schering AG will add imaging agents to the firm's diagnostics portfolio and boost testing-related revenue by roughly two-thirds to $4.5 bil. annually
Bayer's $1.1 Bil. Chiron Diagnostics Buy Adds Blood Gas Analyzer Line
Acquisition of Chiron Diagnostics for $1.1 bil. provides Bayer with an entry into the blood gas analysis market, broadens clinical laboratory systems offerings and will accelerate development efforts in the field of nucleic acid diagnostics.